Search results
Showing 76 to 90 of 374 results for eq-5d
Evidence-based recommendations on darolutamide (Nubeqa) for treating hormone-relapsed prostate cancer in adults at high risk of developing metastatic disease.
Evidence-based recommendations on blinatumomab (Blincyto) with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia in adults.
Evidence-based recommendations on fremanezumab (Ajovy) for preventing migraine in adults.
Selective internal radiation therapies for treating hepatocellular carcinoma (TA688)
Evidence-based recommendations on selective internal radiation therapies SIR-Spheres (Sirtex), TheraSphere (BTG) and QuiremSphere (Quirem Medical) for treating hepatocellular carcinoma in adults.
outcome measures) both health-related quality of life (measured using the EQ-5D) and health service resource use, to enable the results...
outcome measures) both health-related quality of life (measured using the EQ-5D) and health service resource use, to enable the results...
Sarilumab for moderate to severe rheumatoid arthritis (TA485)
Evidence-based recommendations on sarilumab (Kevzara) for treating moderate to severe rheumatoid arthritis in adults.
Evidence-based recommendations on ganaxolone (Ztalmy) for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over.
Letermovir for preventing cytomegalovirus disease after a stem cell transplant (TA591)
Evidence-based recommendations on letermovir (Prevymis) for preventing cytomegalovirus disease after a stem cell transplant.
Evidence-based recommendations on vismodegib (Erivedge) for treating basal cell carcinoma in adults.
Evidence-based recommendations on baricitinib (Olumiant) for treating severe alopecia areata in adults.
Nintedanib for treating progressive fibrosing interstitial lung diseases (TA747)
Evidence-based recommendations on nintedanib for treating progressive fibrosing interstitial lung diseases in adults.
Evidence-based recommendations on idebenone (Raxone) for treating visual impairment in Leber’s hereditary optic neuropathy in people 12 years and over.
Show all sections
Evidence-based recommendations on belantamab mafodotin (Blenrep) with bortezomib and dexamethasone for previously treated multiple myeloma in adults.
Evidence-based recommendations on vinflunine (Javlor) for treating advanced transitional cell carcinoma of the urothelial tract in adults.